Actos

Land: Europeiska unionen

Språk: engelska

Källa: EMA (European Medicines Agency)

Köp det nu

Bipacksedel Bipacksedel (PIL)
28-08-2023
Produktens egenskaper Produktens egenskaper (SPC)
28-08-2023

Aktiva substanser:

pioglitazone hydrochloride

Tillgänglig från:

CHEPLAPHARM Arzneimittel GmbH

ATC-kod:

A10BG03

INN (International namn):

pioglitazone

Terapeutisk grupp:

Drugs used in diabetes

Terapiområde:

Diabetes Mellitus, Type 2

Terapeutiska indikationer:

Pioglitazone is indicated in the treatment of type-2 diabetes mellitus:as monotherapy:in patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance;as dual oral therapy in combination with:metformin, in patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin;a sulphonylurea, only in patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea;as triple oral therapy in combination with:metformin and a sulphonylurea, in patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.Pioglitazone is also indicated for combination with insulin in type-2 diabetes mellitus patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance.

Produktsammanfattning:

Revision: 30

Bemyndigande status:

Authorised

Tillstånd datum:

2000-10-13

Bipacksedel

                                28
B. PACKAGE LEAFLET
29
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
ACTOS 15 MG TABLETS
ACTOS 30 MG TABLETS
ACTOS 45 MG TABLETS
pioglitazone
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Actos is and what it is used for
2.
What you need to know before you take Actos
3.
How to take Actos
4.
Possible side effects
5.
How to store Actos
6.
Contents of the pack and other information
1.
WHAT ACTOS IS AND WHAT IT IS USED FOR
Actos contains pioglitazone. It is an anti-diabetic medicine used to
treat type 2 (non-insulin dependent)
diabetes mellitus in adults, when metformin is not suitable or has
failed to work adequately. This is the
diabetes that usually develops in adulthood.
Actos helps control the level of sugar in your blood when you have
type 2 diabetes by helping your
body make better use of the insulin it produces. Your doctor will
check whether Actos is working 3 to
6 months after you start taking it.
Actos may be used on its own in patients who are unable to take
metformin, and where treatment with
diet and exercise has failed to control blood sugar or may be added to
other therapies (such as
metformin, sulphonylurea or insulin) which have failed to provide
sufficient control of blood sugar.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE ACTOS
DO NOT TAKE ACTOS
-
if you are allergic to pioglitazone or any of the other ingredients of
this medicine (listed in
section 6).
-
if you have heart failure or have had heart failure in the past.
-
if you have liver disease.
-
if you have had diabetic ketoa
                                
                                Läs hela dokumentet
                                
                            

Produktens egenskaper

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Actos 15 mg tablets
Actos 30 mg tablets
Actos 45 mg tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Actos 15 mg tablets
Each tablet contains 15 mg of pioglitazone (as hydrochloride).
_Excipient with known effect_
Each tablet contains 92.87 mg of lactose monohydrate (see section
4.4).
Actos 30 mg tablets
Each tablet contains 30 mg of pioglitazone (as hydrochloride).
_Excipient with known effect_
Each tablet contains 76.34 mg of lactose monohydrate (see section
4.4).
Actos 45 mg tablets
Each tablet contains 45 mg of pioglitazone (as hydrochloride).
_Excipient with known effect_
Each tablet contains 114.51 mg of lactose monohydrate (see section
4.4).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Tablet
Actos 15 mg tablets
The tablets are white to off-white, round, convex and marked ‘15’
on one face and ‘ACTOS’ on the
other face.
Actos 30 mg tablets
The tablets are white to off-white, round, flat and marked ‘30’ on
one face and ‘ACTOS’ on the other
face.
Actos 45 mg tablets
The tablets are white to off-white, round, flat and marked ‘45’ on
one face and ‘ACTOS’ on the other
face.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Pioglitazone is indicated as second or third line treatment of type 2
diabetes mellitus as described
below:
3
as
MONOTHERAPY
-
in adult patients (particularly overweight patients) inadequately
controlled by diet and
exercise for whom metformin is inappropriate because of
contraindications or
intolerance
as
DUAL ORAL THERAPY
in combination with
-
metformin, in adult patients (particularly overweight patients) with
insufficient
glycaemic control despite maximal tolerated dose of monotherapy with
metformin
-
a sulphonylurea, only in adult patients who show intolerance to
metformin or for
whom metformin is contraindicated, with insufficient glycaemic control
despite
maximal tolerated dose of monotherapy with a sulphonylurea.
as
TRIPLE ORAL THERAPY
in combination 
                                
                                Läs hela dokumentet
                                
                            

Dokument på andra språk

Bipacksedel Bipacksedel bulgariska 28-08-2023
Produktens egenskaper Produktens egenskaper bulgariska 28-08-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport bulgariska 29-09-2016
Bipacksedel Bipacksedel spanska 28-08-2023
Produktens egenskaper Produktens egenskaper spanska 28-08-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport spanska 29-09-2016
Bipacksedel Bipacksedel tjeckiska 28-08-2023
Produktens egenskaper Produktens egenskaper tjeckiska 28-08-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport tjeckiska 29-09-2016
Bipacksedel Bipacksedel danska 28-08-2023
Produktens egenskaper Produktens egenskaper danska 28-08-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport danska 29-09-2016
Bipacksedel Bipacksedel tyska 28-08-2023
Produktens egenskaper Produktens egenskaper tyska 28-08-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport tyska 29-09-2016
Bipacksedel Bipacksedel estniska 28-08-2023
Produktens egenskaper Produktens egenskaper estniska 28-08-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport estniska 29-09-2016
Bipacksedel Bipacksedel grekiska 28-08-2023
Produktens egenskaper Produktens egenskaper grekiska 28-08-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport grekiska 29-09-2016
Bipacksedel Bipacksedel franska 28-08-2023
Produktens egenskaper Produktens egenskaper franska 28-08-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport franska 29-09-2016
Bipacksedel Bipacksedel italienska 28-08-2023
Produktens egenskaper Produktens egenskaper italienska 28-08-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport italienska 29-09-2016
Bipacksedel Bipacksedel lettiska 28-08-2023
Produktens egenskaper Produktens egenskaper lettiska 28-08-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport lettiska 29-09-2016
Bipacksedel Bipacksedel litauiska 28-08-2023
Produktens egenskaper Produktens egenskaper litauiska 28-08-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport litauiska 29-09-2016
Bipacksedel Bipacksedel ungerska 28-08-2023
Produktens egenskaper Produktens egenskaper ungerska 28-08-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport ungerska 29-09-2016
Bipacksedel Bipacksedel maltesiska 28-08-2023
Produktens egenskaper Produktens egenskaper maltesiska 28-08-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport maltesiska 29-09-2016
Bipacksedel Bipacksedel nederländska 28-08-2023
Produktens egenskaper Produktens egenskaper nederländska 28-08-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport nederländska 29-09-2016
Bipacksedel Bipacksedel polska 28-08-2023
Produktens egenskaper Produktens egenskaper polska 28-08-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport polska 29-09-2016
Bipacksedel Bipacksedel portugisiska 28-08-2023
Produktens egenskaper Produktens egenskaper portugisiska 28-08-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport portugisiska 29-09-2016
Bipacksedel Bipacksedel rumänska 28-08-2023
Produktens egenskaper Produktens egenskaper rumänska 28-08-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport rumänska 29-09-2016
Bipacksedel Bipacksedel slovakiska 28-08-2023
Produktens egenskaper Produktens egenskaper slovakiska 28-08-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport slovakiska 29-09-2016
Bipacksedel Bipacksedel slovenska 28-08-2023
Produktens egenskaper Produktens egenskaper slovenska 28-08-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport slovenska 29-09-2016
Bipacksedel Bipacksedel finska 28-08-2023
Produktens egenskaper Produktens egenskaper finska 28-08-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport finska 29-09-2016
Bipacksedel Bipacksedel svenska 28-08-2023
Produktens egenskaper Produktens egenskaper svenska 28-08-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport svenska 29-09-2016
Bipacksedel Bipacksedel norska 28-08-2023
Produktens egenskaper Produktens egenskaper norska 28-08-2023
Bipacksedel Bipacksedel isländska 28-08-2023
Produktens egenskaper Produktens egenskaper isländska 28-08-2023
Bipacksedel Bipacksedel kroatiska 28-08-2023
Produktens egenskaper Produktens egenskaper kroatiska 28-08-2023
Offentlig bedömningsrapport Offentlig bedömningsrapport kroatiska 29-09-2016

Sök varningar relaterade till denna produkt

Visa dokumenthistorik